MedTrace Logo

Ribavirin Bioavailability After Telaprevir Exposure

NCT02881034 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2016-08-29

No results posted yet for this study

Summary

Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone. The objective was to measure the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal function.

Conditions

  • Hepatitis C

Interventions

DRUG

Triple therapy

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881034 on ClinicalTrials.gov